22190-33-6Relevant articles and documents
Efficient synthesis process of medical intermediate 5-bromoindole
-
Paragraph 0036-0037; 0041; 0043-0044; 0048; 0050-0051; 0055, (2020/08/06)
The invention discloses an efficient synthesis process of a medical intermediate 5-bromoindole, comprising the following steps of: using an indole compound as a raw material, carrying out low-pressureliquid-phase hydrogenation to destroy five-membered ring conjugation of indole to obtain an indoline compound; enabling the indoline compound to react with an acylation reagent, and protecting nitrogen, so as to obtain an N-acyl indoline compound; carrying out bromination on the N-acyl indoline compound to obtain a 5-bromo-N-acyl indoline compound; carrying out deacylation protection on the 5-bromo-N-acyl indoline compound to obtain a 5-bromoindoline compound; and carrying out oxidative dehydrogenation on the 5-bromoindoline compound by using oxygen or air under the action of a cuprous catalyst and nitric oxide to obtain the target compound 5-bromoindole. The steps involved in the process are convenient to operate, the conditions are mild, and environmental pollution is reduced; finally,the prepared product is high in yield, high in purity and low in energy consumption.
Preparation method of drug intermediate 5-bromoindole
-
Paragraph 0022, (2017/08/29)
The invention relates to a preparation method of a drug intermediate 5-bromoindole. The preparation method uses an N-acyl indoline compound 3 as a raw material, a 5-bro-N-acyl indoline compound 4 is obtained through bromization, then a 5-bromoindole compound 5 is obtained through diacylation protection, and a target compound 6, namely 5-bromoindole, is obtained through oxidative dehydrogenation. The preparation method is suitable for large-scale production, the production cost is relatively lower, colors can be thoroughly removed through pure recrystallization, and the preparation method has the positive significance on application of the 5-bromoindole and quality control of relevant drugs.
Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
-
Paragraph 0471, (2015/09/22)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.